Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Opioid Induced Constipation (OIC) Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Opioid Induced Constipation (OIC) Drug Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Lubiprostone
      • 1.3.3 Methyl Naltrexone Bromide
      • 1.3.4 Naldemedine
      • 1.3.5 Alvimopan
      • 1.3.6 Other
    • 1.4 Market Segment by Application
      • 1.4.1 Global Opioid Induced Constipation (OIC) Drug Market Share by Application (2019-2025)
      • 1.4.2 Hospital Pharmacies
      • 1.4.3 Retail Pharmacies
      • 1.4.4 Online Pharmacies
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Opioid Induced Constipation (OIC) Drug Market Size
      • 2.1.1 Global Opioid Induced Constipation (OIC) Drug Revenue 2014-2025
      • 2.1.2 Global Opioid Induced Constipation (OIC) Drug Sales 2014-2025
    • 2.2 Opioid Induced Constipation (OIC) Drug Growth Rate by Regions
      • 2.2.1 Global Opioid Induced Constipation (OIC) Drug Sales by Regions 2014-2019
      • 2.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Opioid Induced Constipation (OIC) Drug Sales by Manufacturers
      • 3.1.1 Opioid Induced Constipation (OIC) Drug Sales by Manufacturers 2014-2019
      • 3.1.2 Opioid Induced Constipation (OIC) Drug Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Opioid Induced Constipation (OIC) Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Opioid Induced Constipation (OIC) Drug Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Opioid Induced Constipation (OIC) Drug Market Concentration Ratio (CR5 and HHI)
    • 3.3 Opioid Induced Constipation (OIC) Drug Price by Manufacturers
    • 3.4 Key Manufacturers Opioid Induced Constipation (OIC) Drug Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Opioid Induced Constipation (OIC) Drug Market
    • 3.6 Key Manufacturers Opioid Induced Constipation (OIC) Drug Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Lubiprostone Sales and Revenue (2014-2019)
      • 4.1.2 Methyl Naltrexone Bromide Sales and Revenue (2014-2019)
      • 4.1.3 Naldemedine Sales and Revenue (2014-2019)
      • 4.1.4 Alvimopan Sales and Revenue (2014-2019)
      • 4.1.5 Other Sales and Revenue (2014-2019)
    • 4.2 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Type
    • 4.3 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Type
    • 4.4 Opioid Induced Constipation (OIC) Drug Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Opioid Induced Constipation (OIC) Drug Sales by Application

    6 United States

    • 6.1 United States Opioid Induced Constipation (OIC) Drug Breakdown Data by Company
    • 6.2 United States Opioid Induced Constipation (OIC) Drug Breakdown Data by Type
    • 6.3 United States Opioid Induced Constipation (OIC) Drug Breakdown Data by Application

    7 European Union

    • 7.1 European Union Opioid Induced Constipation (OIC) Drug Breakdown Data by Company
    • 7.2 European Union Opioid Induced Constipation (OIC) Drug Breakdown Data by Type
    • 7.3 European Union Opioid Induced Constipation (OIC) Drug Breakdown Data by Application

    8 China

    • 8.1 China Opioid Induced Constipation (OIC) Drug Breakdown Data by Company
    • 8.2 China Opioid Induced Constipation (OIC) Drug Breakdown Data by Type
    • 8.3 China Opioid Induced Constipation (OIC) Drug Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Opioid Induced Constipation (OIC) Drug Breakdown Data by Company
    • 9.2 Rest of World Opioid Induced Constipation (OIC) Drug Breakdown Data by Type
    • 9.3 Rest of World Opioid Induced Constipation (OIC) Drug Breakdown Data by Application
    • 9.4 Rest of World Opioid Induced Constipation (OIC) Drug Breakdown Data by Countries
      • 9.4.1 Rest of World Opioid Induced Constipation (OIC) Drug Sales by Countries
      • 9.4.2 Rest of World Opioid Induced Constipation (OIC) Drug Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Ironwood Pharmaceuticals
      • 10.1.1 Ironwood Pharmaceuticals Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.1.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.1.5 Ironwood Pharmaceuticals Recent Development
    • 10.2 Daiichi Sankyo Co
      • 10.2.1 Daiichi Sankyo Co Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.2.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.2.5 Daiichi Sankyo Co Recent Development
    • 10.3 Pfizer
      • 10.3.1 Pfizer Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.3.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.3.5 Pfizer Recent Development
    • 10.4 Progenics Pharmaceuticals
      • 10.4.1 Progenics Pharmaceuticals Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.4.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.4.5 Progenics Pharmaceuticals Recent Development
    • 10.5 Shionogi &
      • 10.5.1 Shionogi & Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.5.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.5.5 Shionogi & Recent Development
    • 10.6 Allergan
      • 10.6.1 Allergan Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.6.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.6.5 Allergan Recent Development
    • 10.7 Nektar Therapeutics
      • 10.7.1 Nektar Therapeutics Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.7.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.7.5 Nektar Therapeutics Recent Development
    • 10.8 Purdue Pharma
      • 10.8.1 Purdue Pharma Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.8.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.8.5 Purdue Pharma Recent Development
    • 10.9 S.L.A. Pharma
      • 10.9.1 S.L.A. Pharma Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.9.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.9.5 S.L.A. Pharma Recent Development
    • 10.10 Mundipharma International Limited
      • 10.10.1 Mundipharma International Limited Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Opioid Induced Constipation (OIC) Drug
      • 10.10.4 Opioid Induced Constipation (OIC) Drug Product Introduction
      • 10.10.5 Mundipharma International Limited Recent Development
    • 10.11 Ono Pharmaceutical
    • 10.12 Takeda Pharmaceutical Company Limited
    • 10.13 Theravance Biopharma
    • 10.14 Valeant Pharmaceuticals International
    • 10.15 Cosmo Pharmaceuticals SA
    • 10.16 Daewoong Pharmaceutical
    • 10.17 C.B. Fleet Company
    • 10.18 Sucampo Pharmaceuticals

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Opioid Induced Constipation (OIC) Drug Sales Channels
      • 11.2.2 Opioid Induced Constipation (OIC) Drug Distributors
    • 11.3 Opioid Induced Constipation (OIC) Drug Customers

    12 Market Forecast

    • 12.1 Global Opioid Induced Constipation (OIC) Drug Sales and Revenue Forecast 2019-2025
    • 12.2 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Type
    • 12.3 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Application
    • 12.4 Opioid Induced Constipation (OIC) Drug Forecast by Regions
      • 12.4.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Opioid-induced constipation (OIC) is a common adverse effect experienced by many patients on opioid therapy for chronic pain. OTC medications include stimulant laxatives, stool softeners, and enemas.
      In 2019, the market size of Opioid Induced Constipation (OIC) Drug is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Opioid Induced Constipation (OIC) Drug.

      This report studies the global market size of Opioid Induced Constipation (OIC) Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Opioid Induced Constipation (OIC) Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Ironwood Pharmaceuticals
      Daiichi Sankyo Co
      Pfizer
      Progenics Pharmaceuticals
      Shionogi &
      Allergan
      Nektar Therapeutics
      Purdue Pharma
      S.L.A. Pharma
      Mundipharma International Limited
      Ono Pharmaceutical
      Takeda Pharmaceutical Company Limited
      Theravance Biopharma
      Valeant Pharmaceuticals International
      Cosmo Pharmaceuticals SA
      Daewoong Pharmaceutical
      C.B. Fleet Company
      Sucampo Pharmaceuticals

      Market Segment by Product Type
      Lubiprostone
      Methyl Naltrexone Bromide
      Naldemedine
      Alvimopan
      Other

      Market Segment by Application
      Hospital Pharmacies
      Retail Pharmacies
      Online Pharmacies

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Opioid Induced Constipation (OIC) Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Opioid Induced Constipation (OIC) Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Opioid Induced Constipation (OIC) Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now